Skip Navigation

European Journal of Heart Failure 2009 11(11):1106-1109; doi:10.1093/eurjhf/hfp132
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Emmert, M. Y.
Right arrow Articles by Gruenenfelder, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emmert, M. Y.
Right arrow Articles by Gruenenfelder, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Severe cardiomyopathy following treatment with the tumour necrosis factor-{alpha} inhibitor adalimumab for Crohn's disease

Maximilian Y. Emmert1,*, Sacha P. Salzberg1, Lorenz S. Emmert1, Sohil Behjati1, Andre Plass1, Christian Felix2, Volkmar Falk1 and Juerg Gruenenfelder1

1 Department of Cardiovascular Surgery, University Hospital Zurich, Raemi Street 100, 8091 Zurich, Switzerland
2 Department of Anaesthesia & Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland

* Corresponding author. Tel: +41 44 255 1111, Fax: +41 44 255 1111, E-mail: maximilian_emmert{at}web.de


  Abstract

Adalimumab belongs to the group of tumour necrosis factor-{alpha} inhibitors and has been approved for the treatment Crohn's Disease since 2007. Herein we report a severe adverse reaction to adalimumab in a 25-year-old female patient. One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. In severe cardiogenic shock, the patient required an extracorporeal membrane-oxygenation system for 8 days until cardiac recovery.

Key Words: TNF-{alpha} inhibitor • Adalimumab • Cardiomyopathy • Crohn's disease

Received June 17, 2009; Revised August 16, 2009; Accepted August 26, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.